Amphivena Therapeutics amphivena.com


Public list: Pharma Startups (4733) Cancer Therapeutics (1136)

Amphivena Therapeutics, in collaboration with Affimed, develops bispecific TandAbs for hematologic malignancies. TandAbs are tetravalent bispecific antibody formats that have two binding sites for each antigen. Tandems are tetravalent bispecific antibody formats (~100kD) that recruit tumor destroying T cells to tumor cells. By harnessing the immune system, Amphivena's programs offer potential improvements in efficacy for patients with life-threatening hematologic cancers.

Amphivena Therapeutics, in collaboration with Affimed, develops bispecific TandAbs for hematologic malignancies. TandAbs are tetravalent bispecific antibody formats that have two binding sites for each antigen. Tandems are tetravalent bispecific anti...Show all

Company (Alive / Active)

Phone: 415-994-6455

Fax:

45 Juniper Street
Suite 3
San Francisco, 94103
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Amphivena Therapeutics $26.5M Jul 26, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Amphivena Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Bispecific cd33 and cd3 binding proteins Nov 10, 2015 Oct 31, 2017 Patent
Bispecific cd33 and cd3 binding proteins Mar 09, 2015 Dec 15, 2015 Patent
Methods of using bispecific cd33 and cd3 binding proteins May 26, 2016 Application